Engineered immune cells take on stubborn leukemia
NCT ID NCT03919240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see if this therapy can put the cancer into remission and how long that remission lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA WITH FAILED REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fisrt Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can we make CAR-T cells last longer in leukemia?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot